results suggest the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway have already been identified. Our findings also implicate FGFR4 in the pathogenesis of a subset of lung adenocarcinomas

little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis

Fibroblast growth factor FGF19 and its cognate receptor FGFR4 are coexpressed in primary human liver, lung, and colon tumors and xenograft tissues and in a subset of human colon cancer cell lines, where their interactions are important for tumor growth.

FGFR4 Gly388Arg polymorphism is associated with lung cancer.

Higher FGFR4 expression in RMS tumors was associated with advanced-stage cancer and poor survival, while FGFR4 knockdown in a human RMS cell line reduced tumor growth and experimental lung metastases when the cells were transplanted into mice

identified three kinases with gain-of-function mutations in lung cancer, namely FGFR4, MAP3K9, and PAK5. mutations in these kinases are activating toward the ERK pathway, and targeted depletion of the mutated kinases inhibits proliferation

The genotypes of G388R in FGFR4 gene were in Hardy-Weinberg equilibrium. The percentage of normal homozygotes GG was found to be (48.5%) in breast cancer, (51.8%) in lung cancer. Glycine/arginine was (36.9%) in breast cancer, (42.9%) in lung cancer.

Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse models for breast and lung cancers, we validate the enhanced STAT3 signalling induced by the FGFR4 Arg388-variant in vivo

Our findings indicate that the FGFR4-388Arg variant may play an important role in lung squamous cell carcinoma, which may be mediated by the overactivation of the MAPK pathway.

The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction.

Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.

FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in lung Adenocarcinoma in Taiwan.